Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Abbott Laboratories
(NY:
ABT
)
117.26
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abbott Laboratories
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
40
41
Next >
Abbott Laboratories on track for new highs in 2024
January 25, 2024
Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact.
Via
MarketBeat
Exposures
COVID-19
Cracking The Code: Understanding Analyst Reviews For Abbott Laboratories
January 25, 2024
Via
Benzinga
Stock Market Extends Record Highs, S&P 500 Hits 4,900 On Tech Rally, Microsoft's $3 Trillion Mark: What's Driving Markets Wednesday?
January 24, 2024
It’s a bullish day on Wall Street, with major U.S. large-cap indices reaching record highs, driven by broad-based rallies in tech-related stocks as investors continue to embrace the AI trade.
Via
Benzinga
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
Earnings Preview For Abbott Laboratories
January 23, 2024
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today
January 19, 2024
Via
Benzinga
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
January 11, 2024
Via
Benzinga
Abbott Laboratories (ABT) Q4 2023 Earnings Call Transcript
January 24, 2024
ABT earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Abbott Laboratories Surpasses Q4 Sales Expectations, Despite Dip In COVID-19 Testing Demand
January 24, 2024
Abbott Laboratories exceeds expectations with Q4 sales of $10.24B, showcasing resilience despite softer demand for COVID-19 testing. CEO anticipates continued growth in 2024.
Via
Benzinga
Exposures
COVID-19
Abbott Labs Skids On Light Earnings Guidance Despite Quarterly Sales Beat
January 24, 2024
Abbott beat sales expectations and earnings came in light for the fourth quarter.
Via
Investor's Business Daily
Abbott Laboratories Barely Hits Q4 Target With $1.19 EPS
January 24, 2024
Abbott Laboratories announces Q4 results with $10.24 billion in revenue and an EPS of $1.19.
Via
Talk Markets
Nasdaq, S&P 500 Futures Jump As Wall Street Eagerly Awaits Tesla's Q4 Earnings: Analyst Says Rally Broadening But Favors These Stocks
January 24, 2024
Earnings have served to mitigate early January's weakness, and sentiment appears to be upbeat going into Wednesday's session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Beyond The Numbers: 5 Analysts Discuss Abbott Laboratories Stock
January 03, 2024
Via
Benzinga
Could Abbott Laboratories Stock Help You Become a Millionaire?
January 03, 2024
There is a lot going the company's way, despite recent struggles.
Via
The Motley Fool
Earnings Scheduled For January 24, 2024
January 24, 2024
Companies Reporting Before The Bell • Freeport-McMoRan (NYSE:FCX) is estimated to report quarterly earnings at $0.22 per share on revenue of $5.86 billion.
Via
Benzinga
Investor Optimism Improves Following Earnings Reports; S&P 500 Reaches Another High
January 24, 2024
The CNN Money Fear and Greed index showed a further increase in overall market sentiment, while the index remained in the "Greed" zone on Tuesday. U.S. stocks closed mixed on Tuesday, with the Dow...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Netflix, Tesla And 3 Stocks To Watch Heading Into Wednesday
January 24, 2024
With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
January 23, 2024
Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.
Via
Benzinga
7 Safe-Haven Stocks to Protect Your Portfolio During a Recession
January 23, 2024
We may not be out of the woods yet, which means certain stable enterprises should be on your radar.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
January 23, 2024
Via
Benzinga
Johnson & Johnson's stock price is at a critical turning point
January 23, 2024
Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Top Stocks To Watch As Earnings Approach
January 23, 2024
Several expansive companies are expected to post stellar quarterly growth when they report Q4 earnings on Wednesday, January 24. Here are a few top-rated stocks to consider as their quarterly results...
Via
Talk Markets
My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024
January 21, 2024
These stocks may help you win in 2024 -- no matter what the market does.
Via
The Motley Fool
S&P 500, Nasdaq, Dow Jones Strike All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday?
January 22, 2024
US stocks rise to record highs on strong earnings reports, with small caps outperforming. Dollar steady, gold down, oil up. Bitcoin tumbles. AMD, TSLA, ADM, GILD, WDC top movers. GE, AAPL, FB, AMZN,...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Medtronic receives FDA approval for deep brain stimulation system
January 17, 2024
Medical device maker Medtronic PLC (NYSE: MDT) received U.S. FDA approval for its implantable medical device called the Percept PC Deep Brain Stimulation (DBS)
Via
MarketBeat
Exposures
Product Safety
Tesla, Netflix, Intel Take Center Stage In Pivotal Q4 Earnings Week As S&P 500 Eyes Breaking New Highs
January 22, 2024
According to Factset, the fourth-quarter earnings season has had a weak start, with the percentage of S&P 500 companies reporting positive earnings surprises below average.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Better Growth Stock: Abbott vs. AbbVie
January 16, 2024
These healthcare giants also offer investors the promise of increasing passive income.
Via
The Motley Fool
Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
January 12, 2024
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. (NYSE: UBER) shares hit an all-time high on Thursda
Via
Benzinga
3 Dividend Kings For Yield And Growth
January 11, 2024
Dividend Kings are known for safe dividends and reliable long-term growth.
Via
Talk Markets
2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade
January 11, 2024
Strong advantages over the competition could allow these businesses to keep raising their dividend payouts for at least another 10 years.
Via
The Motley Fool
Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor
January 08, 2024
From
Tandem Diabetes Care, Inc.
Via
Business Wire
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.